Pharmaceutical industry: latest news

Pharmaceutical industry features

Pharmaceutical industry news from aidsmap

More news

Pharmaceutical industry news selected from other sources

  • Gilead's $1000 hepatitis C pill gets patent in India

    In what could be a major setback to access to treatment in high-burden countries, the Indian Patent Office on Monday granted a patent to Gilead Pharmasset on Sovaldi (sofosbuvir), its blockbuster drug for hepatitis C, for which the company charges $1,000 per pill in the US.

    10 May 2016 | Times of India
  • Sky-high price of hepatitis C drug produces profits for lawmakers

    While patients in Massachusetts await affordable doses of the blockbuster hepatitis C drug Sovaldi, Rep. Joseph Kennedy III has financially benefited from the success of the drug’s manufacturer, Gilead Sciences, according to public financial disclosures and campaign finance records.

    05 May 2016 | Center for Responsive Politics
  • 'Aggressive' pricing helps Merck steal hep C share with newcomer Zepatier

    Merck & Co. has yet to report first-quarter earnings, so industry watchers still don’t know exactly how much market share the company’s new hep C combo treatment, Zepatier, has scored since winning approval in late January. But so far, comments from its competitors suggest it’s doing pretty well for itself.

    03 May 2016 | Fierce Pharma
  • European Commission Grants Marketing Authorization for Gilead’s Fixed-Dose Combination Descovy® (Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV

    Gilead Sciences, Inc. today announced that the European Commission has granted marketing authorization for two doses of Descovy® (emtricitabine and tenofovir alafenamide 200/10 mg and 200/25 mg; F/TAF), a fixed-dose combination for the treatment of HIV-1 infection. Descovy is Gilead’s second TAF-based therapy to receive marketing authorization in the European Union.

    25 April 2016 | Gilead press release
  • Gilead Statement on the Approval of PrEP in Peru

    Gilead Sciences, Inc. is pleased to share that the Peru Ministry of Health has approved the use of once- daily oral Truvada® (emtricitabine 200mg/tenofovir disoproxil fumarate 300mg) as pre-exposure prophylaxis (PrEP), in combination with safer sex practices, to help reduce the risk of sexually acquired HIV-1 infection among uninfected adults at high risk .

    14 April 2016 | Gilead Sciences
  • Innovative new programme set to treat 10,000 patients co-infected with hepatitis C and HIV in Africa and Asia

    The World Hepatitis Alliance welcomes the announcement of a new programme initiated by the Clinton Health Access Initiative, Inc. (CHAI) and AmeriCares that aims to treat 10,000 co-infected HIV and hepatitis C patients in Africa and Asia with new hepatitis C treatment Daklinza (daclatasvir).

    14 April 2016 | World Hepatitis Alliance
  • PrEP Pricing Problems

    A number of barriers to pre-exposure prophylaxis (PrEP) uptake, use, and adherence have been identified—cost shouldn’t be one of them

    02 April 2016 | TAG
  • Greed and the Necessity for Regulation

    The story of U.S. drug pricing run amok isn’t just about corporate arrogance and avarice—it is also about government permissiveness and inaction

    02 April 2016 | TAG
  • GSK eases IP rights for poorest countries, considers patent pooling for cancer

    As the United Nations Secretary General’s High-Level Panel on Access to Medicines initiative continues its work, the GlaxoSmithKline company today announced steps to further help bring innovative medicines to poor countries.

    02 April 2016 | Intellectual Property Watch
  • Mortgages For Expensive Health Care? Some Experts Think It Can Work

    A Massachusetts Institute of Technology economist and Harvard oncologist have a proposal to get highly effective but prohibitively expensive drugs into consumers’ hands: health care installment loans.

    29 March 2016 | Kaiser Health News
More news


Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.